Home / Health / Indian-origin professor's UK firm strikes Covid-19 vaccine deal with India

Indian-origin professor's UK firm strikes Covid-19 vaccine deal with India

The firm, SpyBiotech which is led by Prof Sumi Biswas, is an Oxford University spinoff company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases

oxford, vaccine trials, coronavirus, covid-19

Premium

SpyBiotech said it has signed an exclusive global licensing agreement with SIIPL for the development of the vaccine as part of the study initiated in Australia

Press Trust of India London

4 min read Last Updated : Sep 08 2020 | 10:17 PM IST

An Indian-origin professor's Oxford-based company on Tuesday announced that its Indian partner, the Serum Institute of India (SIIPL), has begun trials of a novel virus-like particle (VLP) vaccine targeting Covid-19 which has the potential to offer a groundbreaking new approach to fighting the pandemic.

Prof Sumi Biswas, Chief Executive Officer and Co-Founder of SpyBiotech – an Oxford University spinoff company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases, said the first subjects have been dosed in a Phase I/II trial.

SpyBiotech said it has signed an exclusive global licensing agreement with SIIPL for the development

Topics : Serum Institute of India Coronavirus Vaccine

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in